BCC Fuba Q2 FY27: consolidated PAT up 150% YoY to ₹3.62 Cr on margin gains, flat QoQ
PAT +150% YoY · revenue +73.9% · margins expanding
₹29.58 Cr
+73.9% YoY
₹3.62 Cr
+150% YoY
12.08%
+3.6pp YoY
₹1.95
BCC Fuba India's consolidated revenue rose 73.9% year-on-year to ₹29.58 Cr in Q2 FY27 (vs ₹17.01 Cr in Q2 FY26), and consolidated PAT climbed 150% YoY to ₹3.62 Cr (vs ₹1.45 Cr) — profit growth running well ahead of the topline, the hallmark of genuine margin expansion rather than a one-off. Sequentially both lines were nearly flat: revenue was up 17.1% QoQ over Q1 FY27's ₹25.27 Cr, but PAT was effectively unchanged (₹3.62 Cr vs ₹3.62 Cr) because Q1 had already booked a ₹1.67 Cr one-time catch-up from finalised customer price revisions that inflated that quarter's margins — matching that elevated base without a repeat windfall is the more telling read than the flat headline. Standalone PAT was higher at ₹4.14 Cr (up 186% YoY, EPS ₹2.08 vs consolidated ₹1.95); the gap versus consolidated is entirely the EMS subsidiary IOGEMS Technologies' ₹0.52 Cr quarterly segment loss (₹0.76 Cr for the half).
Q2 FY-2027 vs prior quarters
Margins expanded on a YoY basis — operating margin (EBITDA/revenue) rose to 19.6% from 15.4% a year ago, and net margin to 12.1% from 8.5% — but both compressed from Q1's 23.3%/14.3% for the reason above. Neither quarter carried exceptional items, so the YoY improvement is operating, not accounting. There is no formal management guidance or outlook on record, and no analyst/brokerage coverage was found for this microcap (searched Nov 2026), so vsGuidance and vsStreet are both unknown rather than estimated. The quarter's other context is a capacity build: consolidated PP&E rose to ₹33.10 Cr from ₹22.57 Cr at March-end, with ₹4.71 Cr of capital work-in-progress, funded by a ₹17.04 Cr share issue during the half (paid-up capital rose to ₹19.89 Cr); the subsidiary separately raised ₹5 Cr via OCDs on Aug 20 to fund its own ramp. Corporate actions this quarter — partly-paid shares converted to fully paid, trading-window closure ahead of results, and a board-approved executive pay revision — were procedural with no earnings impact. Going into Q3, the growth and margin-expansion story is real and YoY-driven, but the Q1 price-revision catch-up means this quarter's flat QoQ print is not a slowdown signal — the cleaner read on run-rate comes once comparisons normalise past Q1's one-off.
The stock went into the print at ₹288, down 4.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
W1
Whether IOGEMS (EMS subsidiary) narrows its loss — ₹0.52 Cr this quarter, ₹0.76 Cr for H1 FY27 — now that it has ₹5 Cr of fresh OCD funding.
W2
Whether the ~₹29-30 Cr quarterly revenue run-rate holds without a repeat of Q1's ₹1.67 Cr one-time price-revision catch-up — Q3 FY27 is the cleaner read on organic growth.
W3
EMS segment revenue is still tiny (₹0.16 Cr this quarter vs ₹29.42 Cr for PCBs) despite the subsidiary absorbing losses and ₹5 Cr of OCD capital — watch whether it scales in coming quarters to justify the funding.